Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for lomustine-induced thrombocytopenia at first progression of MGMT promoter-methylated glioblastoma
2020-005429-10Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of romiplostim in glioblastoma (GBM) and Thrombocytopenia, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Dec 2021; status: terminated.
02
Drugs
romiplostim
03
Conditions
glioblastoma (GBM)Thrombocytopenia
Beyond the preview
Go deeper on 2020-005429-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005429-10.